In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cagrilintide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 130 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 28 (28 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 53 · 18 active1 more mentions it but does not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cagrilintide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 1293 | 1,1171067491 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 452421 | 83481717 |
|---|
| Adverse eventsWhole body | 1616 | 50449311 |
|---|
| Heart functionCardiovascular | 11 | 214198142 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 99 | 185185 |
|---|
| LipidsCardiovascular | 22 | 14313733 |
|---|
| Blood pressureCardiovascular | 33 | 1201182 |
|---|
| Appetite and food intakeMetabolic and weight | 1111 | 1129517 |
|---|
| PharmacokineticsPharmacology | 10811 | 969231 |
|---|
| Receptor activity and mechanismPharmacology | 853 | 8250626 |
|---|
| MortalityWhole body | 22 | 504217 |
|---|
| Hormone levelsEndocrine and hormones | 11 | 3737 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cagrilintide differs from Amylin, human (islet amyloid polypeptide) at 6 positions and carries 2 added groups.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 53 trials, ranked by phase, then posted results and enrollment: 2 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S7,101 participants1 Mar 2023 to est. 14 Oct 2027
Cardiovascular Disease
Novo Nordisk A/S3,400 participants1 Nov 2022 to est. 19 Oct 2026
Obesity
Novo Nordisk A/S2,734 participants27 Sept 2023 to 6 Jan 2026
Type 2 Diabetes Mellitus
1 more mentions it but does not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Cagrilintide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in percentage points | −0.9 percentage points HbA1c change from baseline Dose studied: 2.4 mg once weekly (escalated)32 weeksn = 302023 | −0.64 percentage points HbA1c change Placebo: 0.42 percentage points Dose studied: up to 1.8 mg per day26 weeksn = 1342019 |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h | 159 to 195 h Half-life · cagrilintide 0.16-4.5 mg Dose studied: 0.16-4.5 mgn not reported2021 | 12.6 h |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 20 to 47% Nausea · cagrilintide 0.3-4.5 mg Placebo: 18% Dose studied: 0.3-4.5 mgn not reported2021 | |
| Adverse eventsMetabolic and weightCompared as: share of people in the arm that got the peptide, in % | 97% Participants with adverse events · cagrilintide 0.16-4.5 mg Placebo: 96% Dose studied: 0.16-4.5 mgn = 952021 |
−0.9 percentage points
HbA1c change from baseline
Dose studied: 2.4 mg once weekly (escalated)32 weeksn = 302023
−0.64 percentage points
HbA1c change
Placebo: 0.42 percentage points
Dose studied: up to 1.8 mg per day26 weeksn = 1342019
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cagrilintide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in sds | No comparable result 11 randomized-trial results measure it in another way or another unit. | −0.22 SDS Estimated difference in BMI SDS Dose studied: 3.0 mg56 weeksn = 2512020 |
half-life · NN2211 s.c.
Dose studied: 1.25-12.5 microg/kgseven daysn not reported2002
21% Nausea · liraglutide 1.8 mg Dose studied: 1.8 mg once daily26 weeksn = 9112013 |
56.3% Participants with adverse events Placebo: 62.5% Dose studied: 0.3 mg start, weekly escalation up to 3.0 mg or maximum tolerated dosen = 242019 |
159 to 195 h
Half-life · cagrilintide 0.16-4.5 mg
Dose studied: 0.16-4.5 mgn not reported2021
12.6 h
half-life · NN2211 s.c.
Dose studied: 1.25-12.5 microg/kgseven daysn not reported2002
20 to 47%
Nausea · cagrilintide 0.3-4.5 mg
Placebo: 18%
Dose studied: 0.3-4.5 mgn not reported2021
21%
Nausea · liraglutide 1.8 mg
Dose studied: 1.8 mg once daily26 weeksn = 9112013
97%
Participants with adverse events · cagrilintide 0.16-4.5 mg
Placebo: 96%
Dose studied: 0.16-4.5 mgn = 952021
56.3%
Participants with adverse events
Placebo: 62.5%
Dose studied: 0.3 mg start, weekly escalation up to 3.0 mg or maximum tolerated dosen = 242019
| Heart functionCardiovascularCompared as: difference from placebo, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 4.7% Difference in LVEF change Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016 |
|---|
| Hormone levelsEndocrine and hormonesCompared as: value in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | −21% Angiotensin II decrease · Shown as a change. The study reports a angiotensin ii decrease of this size. Dose studied: 1.2 mgsingle dosen = 112016 |
|---|
| LipidsCardiovascularCompared as: difference from placebo, in lipids | No randomized trial result 2 results from other study designs. | 21 lipids Lipids decreased 26 weeksn = 1022021 |
|---|
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in meals/day | No randomized trial result 11 results from other study designs. | −1 meals/day Meal replacements per day difference Dose studied: 1.2 mg per dayn = 522015 |
|---|
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No randomized trial result 8 results from other study designs. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
|---|
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | No randomized trial result 3 results from other study designs. | 4 mm Hg Diastolic nocturnal blood pressure difference Dose studied: 1.8 mg once daily24 weeksn = 1002017 |
|---|
No comparable result
11 randomized-trial results measure it in another way or another unit.
−0.22 SDS
Estimated difference in BMI SDS
Dose studied: 3.0 mg56 weeksn = 2512020
No comparable result
1 randomized-trial result measure it in another way or another unit.
4.7%
Difference in LVEF change
Dose studied: 0.6 mg for 2 days, 1.2 mg for 2 days, then 1.8 mg for 3 days7 daysn = 902016
No comparable result
1 randomized-trial result measure it in another way or another unit.
−21%
Angiotensin II decrease · Shown as a change. The study reports a angiotensin ii decrease of this size.
Dose studied: 1.2 mgsingle dosen = 112016
No randomized trial result
2 results from other study designs.
21 lipids
Lipids decreased
26 weeksn = 1022021
No randomized trial result
11 results from other study designs.
−1 meals/day
Meal replacements per day difference
Dose studied: 1.2 mg per dayn = 522015
No randomized trial result
8 results from other study designs.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026
No randomized trial result
3 results from other study designs.
4 mm Hg
Diastolic nocturnal blood pressure difference
Dose studied: 1.8 mg once daily24 weeksn = 1002017